Author: Zhiheng Xu; Jianmeng Zhou; Yongbo Huang; Xuesong Liu; Yonghao Xu; Sibei Chen; Dongdong Liu; Zhimin Lin; Xiaoqing Liu; Yimin Li
Title: The efficacy of convalescent plasma for the treatment of severe influenza Document date: 2020_2_23
ID: 4pe9o59g_28
Snippet: All of the 5 studies were multicenter randomized controlled trials. Hung et al had found that hyperimmune IV immunoglobulin (H-IVIG) administrated within 5 days of symptom onset was associated with a lower viral load and reduced mortality in patients with severe H1N1 infection (17) . The pilot study from INSIGHT FLU005 IVIG Pilot Study Group showed that H-IVIG administration significantly increased hemagglutination inhibition (HAI) titer levels a.....
Document: All of the 5 studies were multicenter randomized controlled trials. Hung et al had found that hyperimmune IV immunoglobulin (H-IVIG) administrated within 5 days of symptom onset was associated with a lower viral load and reduced mortality in patients with severe H1N1 infection (17) . The pilot study from INSIGHT FLU005 IVIG Pilot Study Group showed that H-IVIG administration significantly increased hemagglutination inhibition (HAI) titer levels among patients with influenza (18). Later, they performed an international, double-blind RCT, which shown that hIVIG had similar safety outcome of death and adverse events (15) . Furthermore, Beigel et al did a multicenter phase 2 trial and found that immune plasma provided support for a possible benefit of severe influenza (19). Recently, their phase 3 trial had shown that high-titre anti-influenza plasma conferred no significant benefit of severe influenza A (14) ( Table 1) .
Search related documents:
Co phrase search for related documents- adverse event and double blind: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adverse event and immune plasma: 1
- adverse event and multicenter phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adverse event death and control trial: 1
- anti influenza plasma and H1N1 infection: 1
- anti influenza plasma and HAI titer: 1
- anti influenza plasma and hemagglutination inhibition: 1
- anti influenza plasma and high titre: 1
- anti influenza plasma and high titre anti influenza plasma: 1
- anti influenza plasma and immune plasma: 1, 2, 3, 4, 5, 6
- anti influenza plasma and multicenter phase: 1
- control trial and double blind: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- control trial and high titre: 1
- control trial and multicenter phase: 1, 2
- double blind and hemagglutination inhibition: 1, 2
- double blind and high titre: 1, 2
- double blind and immune plasma: 1, 2, 3, 4
- double blind and low viral load: 1
- double blind and multicenter phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date